Multiple sclerosis (MS) is considered as an inflammatory autoimmune disease of the central nervous system (CNS), with a complex and heterogenic etiology. However, the involvement of inflammation in its pathophysiology is well documented and current therapies for MS are mainly immunosuppressive drugs. Although the available drugs reduce new lesions and relapses, their long-term outcome is not completely satisfactory. Inflammasomes are multimeric protein complexes that play a critical role in the inflammatory process. Several lines of evidence suggest an association between inflammasome activation and MS. In this paper, we have reviewed current studies that demonstrate the involvement of inflammasomes in MS development, in both animal model and MS patients. Furthermore, prior studies about the effect of inflammasome inhibitor drugs on development and progression of MS are discussed.

中文翻译：

---

炎症小体在多发性硬化症中的作用

多发性硬化症 (MS) 被认为是一种中枢神经系统 (CNS) 的炎症性自身免疫性疾病，具有复杂的异源性病因。然而，炎症在其病理生理学中的参与是有据可查的，目前对 MS 的治疗主要是免疫抑制药物。虽然现有的药物可以减少新的病变和复发，但它们的长期结果并不完全令人满意。炎症小体是多聚体蛋白复合物，在炎症过程中起关键作用。几条证据表明炎症小体激活与 MS 之间存在关联。在本文中，我们回顾了目前的研究，这些研究证明了炎症小体参与 MS 发展，包括动物模型和 MS 患者。此外，